Brain imaging to study the effects of methylphenidate in adults with ADHD
Multimodal Brain Imaging of the Neural Effects of Methylphenidate in Patients With ADHD
PHASE4 · Johns Hopkins University · NCT04781972
This study is testing how brain scans can help us understand how adults with ADHD respond to the medication methylphenidate compared to a placebo.
Quick facts
| Phase | PHASE4 |
|---|---|
| Study type | Interventional |
| Enrollment | 30 (estimated) |
| Ages | 6 Years to 40 Years |
| Sex | All |
| Sponsor | Johns Hopkins University (other) |
| Locations | 1 site (Baltimore, Maryland) |
| Trial ID | NCT04781972 on ClinicalTrials.gov |
What this trial studies
This study aims to identify neuroimaging biomarkers that can predict how patients with ADHD respond to methylphenidate treatment. It employs a double-blind crossover design where participants will receive both methylphenidate and a placebo, with their brain activity measured using functional MRI and brain chemistry assessed through magnetic resonance spectroscopy. The goal is to understand the neural changes associated with ADHD symptoms and treatment response, which could inform future pharmacological developments for the disorder.
Who should consider this trial
Good fit: Ideal candidates for this study are right-handed adults diagnosed with ADHD - Combined Type.
Not a fit: Patients who are pregnant, have neurological disorders, or contraindications to MRI will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to more personalized and effective treatments for patients with ADHD.
How similar studies have performed: Other studies have explored neuroimaging in ADHD treatment but this specific approach using multimodal imaging with methylphenidate is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * right handed Exclusion Criteria: * pregnant or breast feeding * past or current neurological disorder * non-ADHD cause of cognitive impairment * uncontrolled medical disorder * head trauma with loss of consciousness in the last year or any evidence of functional impairment due to and persisting after head trauma * having an adverse reaction to methylphenidate, or other stimulant medication * having a contraindication to MRI * current smoking
Where this trial is running
Baltimore, Maryland
- Johns Hopkins School of Medicine — Baltimore, Maryland, United States (RECRUITING)
Study contacts
- Principal investigator: Kristin L Bigos, PhD — Johns Hopkins School of Medicine
- Study coordinator: Kristin L Bigos, PhD
- Email: kbigos1@jhu.edu
- Phone: 410-614-0453
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: ADHD - Combined Type